Inhibikase Therapeutics (IKT) Competitors $1.55 -0.17 (-9.88%) As of 09/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock IKT vs. BCYC, CMPS, CMPX, RGNX, ITOS, CRVS, ZYBT, PRTA, ALMS, and ZVRAShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Bicycle Therapeutics (BCYC), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), Corvus Pharmaceuticals (CRVS), Zhengye Biotechnology (ZYBT), Prothena (PRTA), Alumis (ALMS), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors Bicycle Therapeutics COMPASS Pathways Compass Therapeutics REGENXBIO iTeos Therapeutics Corvus Pharmaceuticals Zhengye Biotechnology Prothena Alumis Zevra Therapeutics Inhibikase Therapeutics (NASDAQ:IKT) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations. Which has stronger earnings and valuation, IKT or BCYC? Inhibikase Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K444.25-$27.52MN/AN/ABicycle Therapeutics$35.28M14.81-$169.03M-$3.51-2.15 Do analysts rate IKT or BCYC? Bicycle Therapeutics has a consensus price target of $22.22, indicating a potential upside of 194.72%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media favor IKT or BCYC? In the previous week, Bicycle Therapeutics had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 2 mentions for Inhibikase Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.94 beat Inhibikase Therapeutics' score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, IKT or BCYC? Inhibikase Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Is IKT or BCYC more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -1,257.00%. Bicycle Therapeutics' return on equity of -32.43% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -63.82% -58.03% Bicycle Therapeutics -1,257.00%-32.43%-26.80% Do institutionals and insiders have more ownership in IKT or BCYC? 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryBicycle Therapeutics beats Inhibikase Therapeutics on 11 of the 14 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$128.17M$269.50M$2.51B$10.39BDividend YieldN/AN/A2.49%4.64%P/E RatioN/AN/A26.4526.11Price / Sales444.25339.99104.09124.93Price / CashN/AN/A50.0461.24Price / Book1.132.8033.746.30Net Income-$27.52M-$111.70M$13.51M$271.03M7 Day Performance-5.49%12.92%-0.69%-0.15%1 Month PerformanceN/A-30.95%2.74%6.41%1 Year PerformanceN/A130.00%66.52%28.81% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics0.0022 of 5 stars$1.55-9.9%N/AN/A$128.17M$260K0.006BCYCBicycle Therapeutics3.4852 of 5 stars$6.93-3.2%$22.22+220.7%-67.7%$480.30M$19.28M-1.97240CMPSCOMPASS Pathways2.7016 of 5 stars$4.90-3.5%$16.29+232.4%-17.1%$470.11MN/A-2.66120Positive NewsCMPXCompass Therapeutics2.6034 of 5 stars$3.39-7.9%$13.88+309.3%+101.7%$468.77M$850K-7.5320High Trading VolumeRGNXREGENXBIO4.6128 of 5 stars$8.89-5.0%$28.38+219.2%-13.6%$449.03M$83.33M-2.58370Positive NewsITOSiTeos Therapeutics2.682 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsCRVSCorvus Pharmaceuticals2.2488 of 5 stars$5.87-4.1%$13.00+121.5%+27.1%$437.37MN/A-5.8130High Trading VolumeZYBTZhengye BiotechnologyN/A$9.23-2.5%N/AN/A$435.38M$25.53M0.00278Gap UpPRTAProthena3.108 of 5 stars$8.07-1.3%$19.75+144.7%-54.2%$434.41M$135.16M-1.43130Positive NewsALMSAlumis3.468 of 5 stars$4.17-2.8%$20.17+383.6%-65.3%$433.93MN/A0.00N/APositive NewsHigh Trading VolumeZVRAZevra Therapeutics2.7396 of 5 stars$7.67-3.4%$23.71+209.2%+26.1%$430.52M$23.61M-36.5220News CoverageOptions VolumeGap Up Related Companies and Tools Related Companies Bicycle Therapeutics Competitors COMPASS Pathways Competitors Compass Therapeutics Competitors REGENXBIO Competitors iTeos Therapeutics Competitors Corvus Pharmaceuticals Competitors Zhengye Biotechnology Competitors Prothena Competitors Alumis Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IKT) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts